[Anti-arrhythmia and hemodynamic effects of allapinin during a course therapy in patients with circulatory failure].
The antiarrhythmic effects of allapinine were studied in 57 patients with chronic circulatory failure (CCF) and cardiac arrhythmias by employing 48-hour Holter monitoring. Allapinine was found to suppress premature ventricular contraction, group premature ventricular contraction and 'runs' of ventricular tachycardia by 82.5, 88.6, and 93.1%, respectively. The antiarrhythmic activity of the agent was more pronounced in patients with coronary heart disease, Stages I-IIA CCF and left ventricular ejection fraction greater than 40%. In addition, in Stages I-IIA CCF allapinine increased myocardial contractility and left ventricular ejection fraction, whereas in Stages IIB-III CCF it showed a slight cardiodepressive effect. Thus, when given in the course therapy in patients with CCF, allapinine has a high antiarrhythmic activity and, to a lesser extent, affects central hemodynamics.
Khodzhakuliev
B G
BG
Naumov
V G
VG
Blinov
S I
SI
Grigor'iants
R A
RA
D000157:Aconitine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology; D002311:Cardiomyopathy, Dilated / Q000503:physiopathology; D003327:Coronary Disease / Q000503:physiopathology; D015716:Electrocardiography, Ambulatory; D005260:Female; D006331:Heart Diseases / Q000503:physiopathology*; D006349:Heart Valve Diseases / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged
D000889:Anti-Arrhythmia Agents; C051402:allapinin; D000157:Aconitine
Antiaritmicheskoe i gemodinamicheskoe deĭstvie allapinina pri kursovom primenenii u bol'nykh s nedostatochnost'iu krovoobrashcheniia.